Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
schizophrenia
Pharma
15 years later, Vanda secures another FDA nod for Fanapt
The FDA has signed off on Vanda Pharmaceuticals' Fanapt to treat adults with manic or mixed episodes associated with bipolar I disorder.
Kevin Dunleavy
Apr 3, 2024 11:04am
Teva, Viatris revive patent challenge on J&J schizophrenia drug
Apr 2, 2024 11:12am
Acadia gives up on future Nuplazid studies after latest flop
Mar 12, 2024 11:58am
Alkermes reports strong trajectory for Lybalvi, shares up 10%
Feb 15, 2024 1:10pm
Teva rolls along in 2nd year of 'Pivot to Growth' strategy
Jan 31, 2024 3:06pm
BMS-BeiGene, Sumitomo-Otsuka, AstraZeneca—Fierce Pharma Asia
Aug 4, 2023 8:50am